Cargando…

Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics

To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjug...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Bau-Yen, Kuthati, Yaswanth, Kankala, Ranjith Kumar, Kankala, Shravankumar, Deng, Jin-Pei, Liu, Chen-Lun, Lee, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304787/
https://www.ncbi.nlm.nih.gov/pubmed/28347114
http://dx.doi.org/10.3390/nano5042169
_version_ 1782506946542174208
author Hung, Bau-Yen
Kuthati, Yaswanth
Kankala, Ranjith Kumar
Kankala, Shravankumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
author_facet Hung, Bau-Yen
Kuthati, Yaswanth
Kankala, Ranjith Kumar
Kankala, Shravankumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
author_sort Hung, Bau-Yen
collection PubMed
description To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjugated with glutaraldehyde. Consequently, the enzymes could be stabilized in nanochannels through the formation of covalent imine bonds. This strategy was used to protect HRP from immune exclusion, degradation and denaturation under biological conditions. Furthermore, immobilization of HRP in the nanochannels of IBN-4 nanomaterials exhibited good functional stability upon repetitive use and long-term storage (60 days) at 4 °C. The generation of functionalized and HRP-immobilized nanomaterials was further verified using various characterization techniques. The possibility of using HRP-encapsulated IBN-4 materials in prodrug cancer therapy was also demonstrated by evaluating their ability to convert a prodrug (indole-3-acetic acid (IAA)) into cytotoxic radicals, which triggered tumor cell apoptosis in human colon carcinoma (HT-29 cell line) cells. A lactate dehydrogenase (LDH) assay revealed that cells could be exposed to the IBN-4 nanocomposites without damaging their membranes, confirming apoptotic cell death. In summary, we demonstrated the potential of utilizing large porous mesoporous silica nanomaterials (IBN-4) as enzyme carriers for prodrug therapy.
format Online
Article
Text
id pubmed-5304787
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53047872017-03-21 Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics Hung, Bau-Yen Kuthati, Yaswanth Kankala, Ranjith Kumar Kankala, Shravankumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung Nanomaterials (Basel) Article To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjugated with glutaraldehyde. Consequently, the enzymes could be stabilized in nanochannels through the formation of covalent imine bonds. This strategy was used to protect HRP from immune exclusion, degradation and denaturation under biological conditions. Furthermore, immobilization of HRP in the nanochannels of IBN-4 nanomaterials exhibited good functional stability upon repetitive use and long-term storage (60 days) at 4 °C. The generation of functionalized and HRP-immobilized nanomaterials was further verified using various characterization techniques. The possibility of using HRP-encapsulated IBN-4 materials in prodrug cancer therapy was also demonstrated by evaluating their ability to convert a prodrug (indole-3-acetic acid (IAA)) into cytotoxic radicals, which triggered tumor cell apoptosis in human colon carcinoma (HT-29 cell line) cells. A lactate dehydrogenase (LDH) assay revealed that cells could be exposed to the IBN-4 nanocomposites without damaging their membranes, confirming apoptotic cell death. In summary, we demonstrated the potential of utilizing large porous mesoporous silica nanomaterials (IBN-4) as enzyme carriers for prodrug therapy. MDPI 2015-12-04 /pmc/articles/PMC5304787/ /pubmed/28347114 http://dx.doi.org/10.3390/nano5042169 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hung, Bau-Yen
Kuthati, Yaswanth
Kankala, Ranjith Kumar
Kankala, Shravankumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title_full Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title_fullStr Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title_full_unstemmed Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title_short Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
title_sort utilization of enzyme-immobilized mesoporous silica nanocontainers (ibn-4) in prodrug-activated cancer theranostics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304787/
https://www.ncbi.nlm.nih.gov/pubmed/28347114
http://dx.doi.org/10.3390/nano5042169
work_keys_str_mv AT hungbauyen utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT kuthatiyaswanth utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT kankalaranjithkumar utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT kankalashravankumar utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT dengjinpei utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT liuchenlun utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics
AT leechiahung utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics